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Abstract
Patients with moderate to severe malignancy-related pain frequently require the use of opioid
pharmacotherapy. Unfortunately, many cancer patients continue to be prescribed subtherapeutic
doses of pain medications resulting in undo suffering and diminished quality of life. The choice of
analgesic pharmacotherapy should be individualized and based on the intensity and etiology of pain
reported by the patient. Health care providers must be able to readily quantify the relative analgesic
potency when converting from one opioid to another or from one route of administration to
another. Transdermal fentanyl is effective and well tolerated pharmacotherapy for the cancer pain
patients. However, clinicians need to be cognizant that the U.S./U.K. manufacturer's
recommendations for equilalagesic dosing of transdermal fentanyl may result in initial doses that
produce subtherapeutic levels and unrelieved pain in some patients. A more aggressive dosing
algorithm for transdermal fentanyl using a 2:1 (mg/day of oral morphine: mcg/hr of transdermal
fentanyl) conversion ratio that considers both a review of the literature and clinical experience
should help clinicians individualize cancer pain pharmacotherapy. Transdermal buprenorphine is
now being prescribed in Europe and Australia for chronic and cancer pain management.
Buprenorphine's mixed agonist/antagonist activity, dosage ceiling, and high affinity to the opiate
receptor limits its use to those patients who do not already require large daily doses of opioids.
Thus, buprenorphine may not be an appropriate medication for some patients with advanced
unremitting cancer pain.
Review
Management of malignancy-related pain continues to be
a major problem due to undertreatment and/or inade-
quate selection of adjunctive medications and other
modalities combined with opioid therapy. Significant
pain is reported in at least one-third of newly diagnosed
oncology patients, and 65 to 85 percent of those with
advanced disease [1,2]. A broad spectrum of pharmaco-
therapy is currently available to appropriately manage
approximately 90 percent of patients with cancer pain.
Unfortunately, many of these patients remain at subther-
apeutic doses and continue to experience suboptimal pain
control [2-4]. Pain associated with malignancy and its
treatment may exacerbate other symptoms associated
with cancer including nausea, fatigue, depression, anxiety,
weakness, dyspnea, constipation, and impaired cognition
[1-6]. Additionally, uncontrolled pain diminishes quality
of life and, patients experiencing pain often hesitate in
participating in activities of daily living (ADLs) for fear of
worsening their pain. Thus, social and family relation-
ships may suffer as this avoidance behavior escalates [6,7].
A thorough pain assessment must be conducted on each
patient. This assessment should include pain severity and
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etiology, age, extent of disease, previously effective and
ineffective therapies, concurrent medical problems, and
psychosocial status. It is important to note that the care
plan for each patient must be individualized, regularly
reassessed, and adjusted, if necessary, to maximize pain
control and quality of life [3,5,6]. The patient's self-report
is very important, as it has been documented that both
caregivers and health care workers tend to underestimate
pain severity [3,7].
The World Health Organization (WHO) pain manage-
ment guidelines suggest that the choice of analgesic phar-
macotherapy be based on the intensity of pain reported by
the patient, not simply its specific etiology [8-10]. Opio-
ids such as morphine, hydromorphone, oxycodone, fen-
tanyl, and buprenorphine, have been shown to be highly
effective in alleviating moderate to severe malignant and
nonmalignant chronic pain that is not of neuropathic ori-
gin [11-14].
Traditional transdermal dosing conversion
Table 1 provides the manufacturer recommended relative
oral morphine to transdermal fentanyl conversion com-
monly utilized by health care practitioners (HCPs) [15-
21]. Patients should be titrated to adequate pain relief
with short acting pain medications prior to the initiation
of transdermal fentanyl in order to prevent exacerbation
of pain or opioid-related adverse effects [22]. Addition-
ally, the manufacturer recommends the following steps to
convert patients from oral or parenteral opioids to
transdermal fentanyl [20,21]:
1. Calculate the previous 24-hour analgesic requirements.
2. Convert this amount to the equianalgesic oral mor-
phine dose.
3. Determine the calculated 24-hour oral morphine dose
and corresponding transdermal fentanyl dose.
4. Initiate treatment using this recommended dose, and
titrate dosage upward (no more frequently than every 3
days after administering the initial dose or every 6 days
thereafter) until analgesic efficacy is attained.
Unfortunately, the aforementioned manufacturer's rec-
ommended dosing conversions for transdermal fentanyl
provided in Table 1 have been found to underestimate the
dosing needs of chronic pain sufferers [22,23]. These sub-
therapeutic starting doses result in breakthrough pain dur-
ing initial titration because of failure to increase fentanyl
dosages upward in the first 72 hours of therapy. A more
aggressive dosing approach is required in the manage-
ment of malignant pain. Therefore, when titrating the
dosage of the transdermal fentanyl, the HCP must con-
sider the daily dose of the immediate release break-
through pain analgesics required by the patient during the
second and third days after initial patch placement and, if
necessary, increase the dose of transdermal fentanyl
within a 72-hour time span, but at least 18 hours after ini-
tiating the currently prescribed patch dose. Moreover, the
transdermal fentanyl system (as opposed to injectable
fentanyl) has an elimination half life of 13 to 22 hours
making it extremely long acting [20]. Thus, it can take as
many as 6 days to achieve steady state serum fentanyl con-
centrations. If the initial starting dose is too low, then the
dosage titration necessary to achieve adequate pain con-
trol may take even longer [20]. Subtherapeutic pain con-
trol is quite distressing for the patient, and can lead to
therapy failure and/or discontinuance of pharmacother-
apy. This problem is accentuated in patients with chronic
pain who have been exposed to opioids previously and
therefore require higher doses of these medications to
control their pain. Opioid-naïve patients typically need
fewer dosage adjustments to reach therapeutic levels.
There have been four case reports in the literature docu-
menting withdrawal syndromes associated with conver-
sion from oral opioids to transdermal fentanyl [24,25].
Table 1: Manufacturer recommended initial fentanyl doses based upon daily oral morphine dose in the US and UK [24]
24-hour Oral Morphine Dose (mg/day) Transdermal Fentanyl Dose (mcg/hr)
45–134 25
135–224 50
225–314 75
315–404 100
405–494 125
495–584 150
585–674 175
675–764 200
765–854 225
855–944 250
945–1034 275
1035–1124 300Health and Quality of Life Outcomes 2006, 4:24 http://www.hqlo.com/content/4/1/24
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Withdrawal symptoms in these cases were linked to phys-
iological effects of too low an estimated equianagesic
starting dose and not related to psychological depend-
ence. Therapeutic fentanyl levels can take 12 to 18 hours
to occur after initial patch application. Thus, patients at
greatest risk for withdrawal are those who are physiologi-
cally dependent and stop taking their oral opioid medica-
tion prior to the first application of the transdermal patch
and/or prior to the achievement of a steady-state fentanyl
serum level. Those patients who are started on a subther-
apeutic dose of transdermal fentanyl at the time of dose
conversion from opioid pharmacotherapy are also at risk
of experiencing withdrawal symptoms and breakthrough
pain.
Dosing algorithm for transdermal fentanyl
Cancer patients require an aggressive approach to their
pain management and the initial dosing transdermal fen-
tanyl. Care must be taken to avoid subtherapeutic dosing
that can compromise patient care and result in uncon-
trolled pain during the initial conversion and titration
period. The conversion table supplied by the manufac-
turer in Germany (Table 2) is much less conservative than
the US/UK table presented in Table 1[20,21,26]. The Ger-
man conversion rate of approximately 2(mg/day):1(mcg/
hr) (60 mg per day of oral morphine is equilanalgesic to
25 mcg per hour of transdermal fentanyl) best translates
into an optimal initial starting dose for the cancer patient
[26]. With this in mind, Figure 1 provides a dosing algo-
rithm for this purpose and Table 3 extrapolates the recom-
mended dose conversion to transdermal fentanyl from
morphine and other commonly employed opioids for
moderate to severe pain [15,26]. Once an approximate
starting dose is calculated, round up or down to the avail-
able patch strength (25 mcg/hr, 50 mcg/hr, 75 mcg/hr,
100 mcg/hr) based on the clinical status of the patient. If
the patient has adequate pain relief from their currently
prescribed pain pharmacotherapy, it is recommended that
the calculated dose be rounded to the nearest patch size
(see Figure 2: Example 1). However, it the patient is expe-
riencing pain at the time of conversion then the dose
should be rounded up to the nearest patch strength (see
Figure 2: Example 2).
A multi-center trial conducted by Donner et al supports
the safety and efficacy of the German recommended
2(mg/day):1(mcg/hr) oral morphine to transdermal fen-
tanyl ratio [23]. The study involved 98 patients with can-
cer-associated pain who were converted directly from
sustained release oral morphine to transdermal fentanyl.
The initial fentanyl dose was calculated by the dose of sus-
tained-release morphine prescribed to the patient prior to
enrollment into the study. The 2(mg/day):1(mcg/hr) con-
version ratio was employed. Breakthrough pain relief was
provided to the patients in the trial through the use of sup-
plemental immediate release liquid morphine as needed.
Pain relief with transdermal fentanyl was similar to that of
sustained release morphine, but the use of supplemental
liquid morphine for breakthrough pain was significantly
higher for those patients receiving transdermal fentanyl.
Constipation was less problematic in patients treated with
fentanyl. There was no significant difference in vital signs
and adverse effects between the two groups. Respiratory
depression was not seen; however three patients experi-
enced morphine withdrawal symptoms within the first 24
hours of transdermal fentanyl therapy. The highest dose
of transdermal fentanyl administered was 500 mcg per
hour.
A more recent study of 1,828 cancer patients who were
either opioid naïve, taking codeine or morphine for their
pain used an average 3(mg/day):1(mcg/hr) conversion
ratio for enrollment into each study group [27]. The
results showed that the 3:1 ratio selected for the initial
dose of transdermal fentanyl was too conservative and all
patients required an escalation in dose to the 2(mg/
day):1(mcg/hr) ratio in the first 48-hours of initial fenta-
nyl therapy. The most common side effect of the study
was constipation with an averaged incidence across the
study groups of 16.6%. The most severe adverse effect of
transdermal fentanyl was nausea but the incidence was
low (1.4%).
Dosage titration and breakthrough pain
Evaluations as to whether the initial starting dose of
transdermal fentanyl is providing adequate pain relief
should be conducted during the first 72 hours after initia-
tion. If the patient requires more than two doses of break-
through medication over a 24-hour period for adequate
Table 2: Recommended initial fentanyl doses based upon daily oral morphine dose in Germany [20,26]
24-hour Oral Morphine Dose (mg/day) Transdermal Fentanyl Dose (mcg/hr)
0–90 25
91–150 50
151–210 75
211–270 100
Every additional 60 mg 25Health and Quality of Life Outcomes 2006, 4:24 http://www.hqlo.com/content/4/1/24
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pain relief, than consideration should be given to increase
the fentanyl patch dose. At low doses of opioids, the patch
is normally increased in 25 mcg per hour increments. It
may be increased in increments of 50 mcg per hour if the
Dosing algorithm for transdermal fentanyl in the cancer patient [adapted from Breitbart et al 28] Figure 1
Dosing algorithm for transdermal fentanyl in the cancer patient [adapted from Breitbart et al 28].
Determine the appropriate starting dose of transdermal fentanyl.
x  Convert to equianalgesic dose of oral morphine using 60mg/day of oral morphine is equivalent to
25 mcg/hr of transdermal patch (~2 mg/day : 1 mcg/hr ratio)
x  Round starting dose of patch up or down to the available patch strength based on clinical status
of the patient.
Ļ
Individualize therapy by titrating to an effective dose.
x  Review pain scores and use of immediate release breakthrough medication.
x  Titrate at 24 to 30 hours, but always by 72 hours, increase dose of patch if necessary.
Ļ
Prevent withdrawal and treat breakthrough pain
x  During titration, prescribe IR opioid previously used. To prevent withdrawal during the first 12-16
hours of initial therapy, give with 10% to 15% of the previous 24-hour opioid dose used
administered every 3 to 4 hours “on schedule.”
x  Patients should be instructed to take additional doses of this IR opioid (at the same dosage as
antiwithdrawal) every 2-4 hours “if needed” for breakthrough pain during titration and thereafter.
x  Breakthrough pain regimens need to be convenient for the patient and of limited frequency
whenever possible. After steady state is reached, if breakthrough pain persists beyond a few
doses each day then an increase in fentanyl dose should be considered. A new the breakthrough
dose should be calculated correspondingly.
x  Care should be taken in adjusting breakthrough and transdermal fentanyl dosing in opiate naïve
patients and in those on low does of transdermal fentanyl (25mcg/hr). These patients may be
adequately maintained on 3 or 4 breakthrough doses each day.
Ļ
Monitor need for new patches
x  Apply a new patch every 72 hours.
x  Increase the dose of the patch, when necessary, to address increased needs for breakthrough
pain relief.
x  Consider applying new patch after 48 hours if more than four doses of rescue medication are
consistently required or for those patients where the analgesic effect of transdermal fentanyl
begins to decline after 48 hours and lasts only for around 60 hours.
IR = immediate release
Table 3: Recommended dose conversion to fentanyl from other selected opioids [15,28]
Transdermal 
Fentanyl (ncg/
hr)
Morphine (mg/day) IM PO Oxycodone (mg/day) IM PO Hydromorphone (mg/day) IM PO
25 20 60 NA 40 3 15
50 40 120 NA 80 6 30
75 60 180 NA 120 9 45
100 80 240 NA 160 12 60
IM = intramuscular; NA = not applicable; PO = oralHealth and Quality of Life Outcomes 2006, 4:24 http://www.hqlo.com/content/4/1/24
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severity of the pain, number of breakthrough doses
required, and total dose of transdermal fentanyl needed
for adequate relief warrants this level of increase. Fifty
(50) mcg incremental dose increases should only be
employed in patients that are not opioid naïve and where
a 50 mcg escalation represents and appropriate percentage
of the entire daily opioid dose. The optimal dose of
transdermal fentanyl should be based on an ongoing eval-
uation of the level of pain relief achieved and the amount
of breakthrough medications utilized. It is important to
note that it can take from 12 to 18 hours to reach a clinical
relevant serum level after initial patch placement. Consist-
ent serum levels are achieved after 16 to 20 hours, and
steady state is attained at about 72 hours [20].
Upon initial dosage titration, and in order to minimize
the risk of opioid withdrawal during the first 16 hours of
transdermal fentanyl therapy, patients should be
instructed to take the prescribed immediate release opioid
every 3 to 4 hours [28]. The dose of "anti-withdrawal"
medication should be equal to 10 to 15 percent of the
total daily dose of opioid that the patient received prior to
the start of fentanyl pharmacotherapy. As an example, if
the patient is applying a 50 mcg per hour fentanyl patch
every 72 hours, the equivalent daily oral dose of oral
immediate release oxycodone is approximately 80mg.
Thus, the patient would be prescribed at least 8 to 12 mg
(10 to 15% of 80 mg) of oxycodone every 3 to 4 hours
(not as needed) for the first 12-16 hours of transdermal
fentanyl pharmacotherapy, and thereafter only as needed.
Some patients may require additional immediate release
doses as frequently as every 2 hours as needed for break-
through pain. Thus, the use of "anti-withdrawal" medica-
tion must be differentiated from breakthrough pain
medication, since the patient mentioned above should
take at least 8 mg of oxycodone every 4 hours to abate
development of withdrawal symptoms during this first 16
hour phase regardless of whether breakthrough medica-
tion is required during that same time period.
Breakthrough pain should be treated with medications
that are simple to administer, offer rapid pain relief, and
have a reasonably short half-life [28]. Immediate release
morphine, hydrocodone, or oxycodone is commonly
used for this purpose [28]. Patients can continue to take
the short-acting opioid that was previously effective for
breakthrough pain [28,29]. Doses of immediate release
pharmacotherapy for breakthrough pain commonly uti-
lized are 10 to 15 percent of the previous total daily opi-
oid dose given every 2-4 hours on an "as needed" basis
[29]. Ideally patients should not take more than two doses
of immediate release breakthrough medication each day
once a steady state serum concentration of fentanyl has
been reached [28,29]. If the breakthrough pain is persist-
ent and requires more than two doses of immediate
release medication during a 24-hour period, then consid-
eration may be given to increasing the transdermal fenta-
nyl dose. At lower transdermal fentanyl doses of 25mcg/
Examples of determining the appropriate initial fentanyl patch size [adapted from Breitbart et al 28] Figure 2
Examples of determining the appropriate initial fentanyl patch size [adapted from Breitbart et al 28].
Example 1:
Patient 1 is taking two oxycodone 5mg plus acetaminophen 325mg every 4 hours and has good
pain control, but would prefer not to take medication every 4 hours. Determine the dose
conversion to initiate transdermal fentanyl patch by converting the total daily dose of oxycodone
(5mg X 2 X 6 = 60mg/day) to an equianalgesic dose of oral morphine (60mg X 1.5 = 90mg/day).
Finally convert the oral morphine to transdermal fentanyl using the 2 (mg/day) : 1 (mcg/hr) oral
morphine to transdermal fentanyl ratio which equals 45mcg/hr of transdermal fentanyl. Since the
patient is well controlled, the dose would be rounded to the nearest patch size or 50mcg/hr.
Example 2:
Patient 2 is on a regimen of 20mg per day of oral hydromorphone and not obtaining adequate
pain relief. Using the 4:1 (morphine:hydromorphone) ratio the hydromorphone converts to
80mg/day of oral morphine. Using the 2 (mg/day) : 1 (mcg/hr) oral morphine to transdermal
fentanyl ratio the oral morphine the dose converts to 40mcg/hr of transdermal fentanyl. Given
the patient’s inadequate pain relief, the dose would be rounded up to a fentanyl patch size of 50
mcg/hr.Health and Quality of Life Outcomes 2006, 4:24 http://www.hqlo.com/content/4/1/24
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hour, however, up to 4 doses of breakthrough medication
may be acceptable without increasing the transdermal
patch dose. For example, if a patient is receiving fentanyl
25mcg/hr with a daily oxycodone PRN breakthrough dose
of 5mg PO 3-4 times per day, it may be too soon to
increase the fentanyl dose, since the next available
transdermal patch size is 50mcg, or twice the current dose.
Comparatively, if the patient is requiring just 3-4 doses of
oxycodone per day (15-20mg), doubling the fentanyl
dose would result in the patient receiving an approxi-
mately 40mg oxycodone increase per day when in fact
only 15-20mg per day was already adequate. Patients who
require an increase in the dose of their around-the-clock
sustained release pharmacotherapy (transdermal fenta-
nyl) as a result of disease progression or other factors
should be given an equivalent increase in the dose of the
breakthrough pain medication.
Patch application considerations
Good adhesion of the fentanyl patch to the skin is essen-
tial for maximum efficacy, therefore patients must be
instructed on the proper technique for patch application
[30]. Hair on the skin should be clipped, not shaved, in
order to avoid abrasions where the patch is to be applied.
This skin should be clean, dry, and undamaged. Soap and/
or topical alcohol-based products should not be used to
cleanse the area immediately prior to patch placement;
water only should be used and the area must be com-
pletely dried. After removal of the plastic backing, the
patch should be held firmly in place for about 30 seconds.
A finger should be run around the edge of the patch to
ensure that adhesion has occurred around all edges. The
top of the patch should be rubbed for approximately 3
minutes. The TTS Multicentre Study Group reported that
82% of patients had no problems with patch adherence
when appropriate technique was employed [31]. There
are some instances where additional adhesion with tape
may be needed especially in warm weather or in patients
who are diaphoretic. Use of an occlusive dressing may be
helpful if tape is insufficient. Patients should also be
instructed to rotate sites when changing patches in order
to minimize changes in serum levels due to build up of
subcutaneous depots, and to minimize skin irritation
[30].
For the majority of patients, the analgesic effect of fenta-
nyl will last for 72 hours and a new patch applied after
that time. Changing fentanyl patches more often than
every 48 hours is not recommended. Many clinicians rec-
ommend increasing the dosage rather than shortening the
dosing interval. However some patients may find that the
effect begins to decline after 48 hours and lasts only for
around 60 hours [32,33]. In these instances, the clinician
should seriously consider changing the fentanyl patch
every 48 hours.
Safety, tolerability, and contraindications
The overall tolerability of transdermal fentanyl is very
good. The most frequently observed adverse effects
include nausea, vomiting and constipation [20,34,35].
Constipation and somnolence occur significantly less fre-
quently with transdermal fentanyl as compared to sus-
tained release oral morphine (constipation: 17% vs. 48%,
respectively, p < 0.001; somnolence: 13% vs. 25%, respec-
tively, p < 0.001) [34,35]. Nausea and vomiting is signifi-
cantly more common with sustained release morphine
than with transdermal fentanyl (31% vs. 28%, respec-
tively, p < 0.001). Skin reactions (i.e. rash, and application
site reactions – erythema, papules, itching, and edema) in
cancer patients have been reported at a frequency between
1 and 2 percent [20]. Opioid withdrawal symptoms (e.g.
nausea, vomiting, diarrhea, anxiety, and shivering) may
occur in some patients after discontinuation of transder-
mal fentanyl, conversion to another opioid, or after low-
ering the fentanyl dosage [21].
Hypoventilation (defined as respiratory rates of less than
8 breaths per minute or a pC02 greater than 55mm Hg)
was reported in three (2%) of the 153 patients with cancer
pain during the pre-marketing trial [21]. However, clinical
relevant fentanyl-induced respiratory depression in
chronic pain patients was not observed in several clinical
trials [27,34-37]. Serious or life-threatening hypoventila-
tion has been documented on opioid-naïve patients and
in postoperative setting. Transdermal fentanyl is therefore
contraindicated in the management of acute or postoper-
ative pain and intermittent, mild pain which can be ade-
quately managed with other pharmacotherapy [21,22].
Transdermal fentanyl should not be administered to chil-
dren under the age of 12 or patients under 18 years old
who weigh less than 50 killigrams [21]. Those with are
hypersensitive to either fentanyl, other phenylpiperidines
(i.e. merperidine, sufentanil, remifentanl, alfentanil), or
the adhesives used in the system should also not receive
this medication [21].
Patients should be instructed to refrain from driving or
operating machinery immediately following the initiation
of transdermal fentanyl, or after any dosage increase
[21,22]. Patients should be warned against the use of elec-
tric blankets, heating pads, hot tubs, saunas, and heat
lamps while wearing transdermal fentanyl patches. The
heat produced by these items can potentially increase the
amount of fentanyl released from the system [21]. Addi-
tionally, fever may enhance fentanyl absorption
[21,34,35]. Therefore, patients who are febrile need to be
monitored for enhanced pharmacological effects and
their dosage adjusted if necessary.
Concomitant use of other centrally acting depressants
such as sedatives, other opoids, hypnotics, phenothi-Health and Quality of Life Outcomes 2006, 4:24 http://www.hqlo.com/content/4/1/24
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azines, tranquillizers, skeletal muscle relaxants, anesthet-
ics, sedating antihistamines, and alcohol can cause
hypoventilation, acute sedation, or hypotension in
patients taking transdermal fentanyl [21]. It is advisable to
reduce the dosages of one or all of these agents when pol-
ytherapy of this nature is considered [21]. Finally, the
transdermal fentanyl reservoir system should not be cut or
damaged, as the integrity of the transdermal system is
destroyed. Safe disposal of the used transdermal fentanyl
systems is important in order to avoid diversion, acciden-
tal poisoning of infants, children, animals, and adults
[21].
Transdermal buprenorphine
Buprenorphine, a centrally acting opioid analgesic, is now
being prescribed in Europe and Australia for chronic and
cancer pain management [38-44]. Buprenorphine is a syn-
thetic opioid which is lipophilic, water soluble, and has a
low molecular weight; these properties allow for tissue
penetration and make it suitable for transdermal delivery
[38,39]. The buprenorphine is contained in a matrix patch
that is applied to the skin for a three-day duration. The
matrix patch differs from the reservoir patch technology.
In a matrix system, the substance is an integral part of the
polymer structure of the patch rendering the buprenor-
phine patch more robust in handling. While damaging a
reservoir patch might result in "dose-dumping" and
potentially overdosing the patient, damaging a matrix
patch does not necessarily interfere with the controlled
release of the medication [38,39].
Transdermal buprenorphine is available with release rates
of 35, 52.5, and 70 micrograms per hour which corre-
sponds to daily doses of 0.8, 1.2, and 1.6 milligrams of
buprenorphine, or approximately 60, 90, and 120 milli-
grams per day equivalent of oral morphine, respectively
[38-41,44]. Steady state serum concentration of buprenor-
phine can take several days to achieve with the transder-
mal formulation. The terminal half-life when delivering
buprenorphine by the transdermal system has been
reported as 25 to 27 hours [38-40,44]. A clinically effec-
tive or analgesia producing serum concentration is
reached in about 12 hours [38-40,44]. Therefore, like
transdermal fentanyl, it is again important to provide
immediate release opioid medication to assist in the pre-
vention of withdrawal symptoms during initial dosage
titration and for treatment of breakthrough pain. How-
ever, in the case of buprenorphine, a less conservative
breakthrough dose regimen may be acceptable, since the
antagonist activity of buprenorphine will help to avoid
additive opioid-induced somnolence.
Buprenorphine TDS has been shown to be quite effective
against chronic, severe pain in three multicenter, rand-
omized, double-blind, placebo-controlled studies [45-
47]. Patients enrolled in these studies had moderate to
severe or severe to very severe chronic pain of malignant
or nonmalignant origin. In patients who were unsuccess-
fully treated with weak opioids or morphine, 36.6% and
47.5% of buprenorphine 35 mcg/hour and 52.5 mcg/
hour recipients, respectively, experienced at least satisfac-
tory analgesia and received ≤ 0.2 mg/day of sublingual
buprenorphine compared with 16.2% response rate for
those receiving placebo (p ≤ 0.05) [45]. The requirement
for breakthrough medication was reduced from baseline
by approximately 50-70% in patients treated with
transdermal buprenorphine [45-47]. Those receiving
transdermal buprenorphine experienced greater pain
relief, reduced pain intensity and longer pain-free sleep
[45-47]. A more recent, multicenter, open-labeled, uncon-
trolled, prospective, observational clinical practice study
involving 1,223 patients with moderate to severe chronic
pain demonstrated that transdermal buprenorphine was
effective in alleviating cancer and non-cancer pain and
was overall well tolerated [48]. These patients also experi-
enced a significant improvement (p < 0.001) in quality of
life scores and reported very good to good pain relief (p <
0.001).
Transdermal delivery of buprenorphine provides for a
slower increase in serum concentration and no peak-and-
trough effects as seen with the sublingual route of admin-
istration. As a result, there are fewer adverse events
reported when using the transdermal delivery system for
this medication [38-44]. Transdermal buprenorphine was
usually well tolerated and adverse events reported in clin-
ical trials were generally mild to moderate in severity. Side
effects included local erythema 26.6%, local pruritis
23.2%, nausea 16.7%, vomiting 9.3%, dizziness 6.8%,
sedation 5.6%, constipation 5.3%, and erythema 4%
[38,45,46]. Adverse events could generally be attributed
to either local skin reactions at the application site,
buprenorphine (systemic events common to opioid
administration), or underlying disease. Adverse events
were more frequently reported in patients with malignant
pain than those without (46.6% vs. 34.2%, respectively).
Transdermal buprenorphine was associated with a low
rate of withdrawals due to adverse events [38,45,46]. In
one study, only 10.8% of the patients withdrew because
of adverse events during a 15-day treatment period [45].
Of very important note is that because buprenorphine is a
mixed opioid agonist/antagonist, it does have a dosage
ceiling [38,39]. Therefore, those patients who are already
on large does of chronic opioids (e.g. 300 mg or more of
oral morphine per day) are not considered appropriate
candidates for transdermal burprenorphine therapy.
Moreover, these patients would be at significant risk of
opioid withdrawal because buprenorphine's affinity for
the opiate receptor is higher than morphine, and the over-Health and Quality of Life Outcomes 2006, 4:24 http://www.hqlo.com/content/4/1/24
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all opiate agonist activity would not be adequate to over-
come the withdrawal symptoms that will otherwise be
seen [38,39]. Finally, transdermal buprenorphine should
not be used in opioid-dependent individuals undergoing
treatment for narcotic withdrawal [39].
Based on the currently available clinical trial data,
transdermal buprenorphine is a valuable alternative to
other available opioids in many chronic pain conditions.
However, despite the positive data presented in these four
clinical trials, more controlled studies are needed to deter-
mine the place of transdermal buprenorphine among cur-
rent treatment strategies for chronic and cancer pain, and
to explore if and whether transdermal buprenorphine
would be of any value in the treatment of difficult pain
conditions such as neuropathic pain.
Conclusion and recommendations
Many pharmacotherapeutic choices are available for the
management of cancer pain. HCPs must be able to readily
quantify the approximate relative analgesic potency when
converting from one opioid to another and from one
route to another. Transdermal formulations of fentanyl
and burprenorphine are very useful pharmacotherapy for
the cancer patient experiencing moderate to severe pain.
Buprenorphine's mixed agonist/antagonist activity, dos-
age ceiling, and high affinity to the opiate receptor limits
its use to those patients who do not already require large
daily doses of opioids. Thus, buprenorphine may not be
an appropriate medication for some patients with
advanced unremitting cancer pain. Clinicians need to be
aware that the relative opioid conversion tables com-
monly utilized are often based on the results of single-
dose studies and frequently underestimate the dosage
required for the cancer pain patient. Generally, a more
aggressive approach to converting a patient to transdermal
fentanyl may be warranted in the cancer patient. Care
must be taken to individualize each patient's pain man-
agement in order to prevent opioid withdrawal and sub-
stantially reduce the undertreatment and overtreatment of
cancer-related pain and its associated negative impact on
patients' quality of life.
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